TRAVERE THERAPEUTICS, INC. Net Change in Cash
TRAVERE THERAPEUTICS, INC. (TVTX) reported Net Change in Cash of $24.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$14.67M, a 536.44% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $3.36M.
- TRAVERE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$14.93M, a 114.97% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $99.69M, a 9.77% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $34.50M, a 9510.03% increase from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $359.00K.
- TRAVERE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$3.51M.
- TRAVERE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$104.06M, a 228.51% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.70M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | -$14.67M 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $34.50M 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $52.40M 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $16.62M 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | $3.36M 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | $359.00K 10-K · filed 2026-02-19 | |||
| 2024-09-30 | -$21.77M 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | -$25.89M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$14.93M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | -$3.51M 10-K · filed 2026-02-19 | |||
| 2023-09-30 | $82.56M 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | $9.19M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $99.69M 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$104.06M 10-K · filed 2025-02-21 | |||
| 2022-09-30 | -$14.42M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $14.01M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $90.82M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $80.98M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | $65.56M 10-Q · filed 2022-10-27 | |||
| 2021-06-30 | -$1.48M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $63.46M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $22.34M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $138.04M 10-Q · filed 2021-10-29 | |||
| 2020-06-30 | $174.73M 10-Q · filed 2021-07-29 | |||
| 2020-03-31 | $4.58M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$40.44M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | -$37.69M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$27.22M 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | -$33.03M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $3.48M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $55.43M 10-Q · filed 2019-10-30 | |||
| 2018-06-30 | -$10.09M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | -$38.28M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $58.39M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |